CSRA Subsidiary DynPort Wins Contract

CSRA subsidiary, DynPort Vaccine Company, won a contract from the National Institute of Allergy and Infectious Diseases to oversee a variety of medical product development projects, the company said Tuesday.

The contract, which has indefinite quantity and delivery parameters, is valued at $159 million and has a performance period of up to 10 years. DynPort will develop processes, testing methods, manufacturing systems and regulatory services to aid in the development of new therapies to treat infectious diseases, the company said.

“Together with our teaming partners, we have the talent and experience base to conduct the wide array of medical product development activities needed by our customer,” said Gary Nabors, president of DynPort.

Leave a Comment